← 產業報告目錄

Migraine Market Research Report Information by Type (Episodic and Chronic), By Treatment Type (Preventive, Abortive), By Drug Class (Triptans, Ergots, and Others), And by Region (North America, Europe, Asia-Pacific, And Rest Of The World) Market Forecast Till 2032

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2025-01-21頁數 206報告編號 MRFRPharma1756HCR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

Migraine Market Research Report Information by Type (Episodic and Chronic), By Treatment Type (Preventive, Abortive), By Drug Class (Triptans, Ergots, and Others), And by Region (North America, Europe, Asia-Pacific, And Rest Of The World) Market Forecast Till 2032 Market Overview In 2023, the migraine market was estimated at USD 5.68 billion. The global migraine industry is expected to expand from USD 6.00 billion in 2024 to USD 8.42 billion by 2032, with a compound annual growth rate (CAGR) of 3.83% over the forecast period (2024-2032). Growing public awareness of innovative medication classes, as well as an increase in migraine disorders worldwide, are significant market drivers boosting growth. Two factors influencing the target market's growth are an increase in migraine cases worldwide and increased public awareness of novel treatment classes. The introduction of calcitonin gene-related peptide (CGRP) is also expected to help this business grow. A migraine is a persistent, severe headache accompanied by nausea, phonophobia, and photophobia. The condition develops in part due to genetics. Emotions out of balance, such as sadness, stress, concern, shock, and exhilaration, can cause migraine headaches. Each migraine episode varies in duration and severity, with most affecting only one side of the head. An increase in the prevalence of migraines with major unmet needs, increased R&D spending resulting in a huge pipeline of drugs, and rising awareness of migraine and treatment choices are all contributing causes. Market Segment insights Migraine market segments include episodic and chronic. Migraine Market segmentation is based on therapy type, which includes preventive and abortive. Surgery has divided the Market statistics into Triptans, Ergots, and Others. Migraine Regional Insights The study covers North America, Europe, Asia-Pacific, and the rest of the world. The Asia Pacific Migraine market is predicted to develop at a considerable CAGR over the study period. The Asia Pacific acute migraine treatment market is predicted to grow due to increased healthcare costs and improved infrastructure in developing countries such as China and India. Another major element that is going to accelerate the regional market is the ease of access to economical migraine treatment choices, which is being backed by expanding regulatory body activities. By the India Brand Equity Foundation. Europe's migraine market has the second-largest market share. The target market's growth is influenced by two factors: growing public knowledge of novel medication classes and a global increase in migraines. Furthermore, the introduction of calcitonin gene-related peptide (CGRP) is expected to accelerate the industry's growth. The North American Migraine Market is predicted to expand at the quickest CAGR between 2024 and 2032. Growing investment from key parties based in the United States. According to estimates, considerable research and development activities in the United States, Canada, and other nations to discover novel treatment choices will boost the domestic market. The American Family Physician estimates that there are around 441.5 million adults in the United States, with 6 to 9 percent men and 18 to 26 percent women. The United States endured a migraine in 2009. Major Players Major competitors in the migraine industry include Sanofi SA, Abbott Laboratories, Teva Pharmaceutical Industries Limited, Allergan Plc, Pfizer Inc, AstraZeneca, Johnson & Johnson, Endo International Plc, GlaxoSmithKline Plc, Impax Laboratories, and others.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ................................................................................ 21 2 MARKET INTRODUCTION ...................................................................... 23 2.1 DEFINITION ..................................................................................................................... 23 2.2 SCOPE OF THE STUDY ................................................................................................ 23 2.3 RESEARCH OBJECTIVE .......................................................................................................... 23 2.4 MARKET STRUCTURE ............................................................................................................. 24 3 RESEARCH METHODOLOGY .......................................................... 25 3.1 OVERVIEW ............................................................................................. 25 3.2 DATA FLOW ................................................................................................................................. 26 3.2.1 DATA MINING PROCESS............................................................................................ 27 3.3 PURCHASED DATABASE: ......................................................................................................... 29 3.4 SECONDARY SOURCES: ......................................................................................................... 30 3.4.1 SECONDARY RESEARCH DATA FLOW: ............................................................................................................. 32 3.5 PRIMARY RESEARCH:............................................................................................... 33 3.5.1 PRIMARY RESEARCH DATA FLOW: ................................................................................................................. 34 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ......................................................................... 35 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE .......................................................... 35 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ............................................... 36 3.6.1 REVENUE ANALYSIS APPROACH ......................................................................... 36 3.7 DATA FORECASTING........................................................................................................... 37 3.7.1 DATA FORECASTING TECHNIQUE ......................................................................... 37 3.8 DATA MODELING ............................................................................................. 38 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ....................................................................... 38 3.8.2 DATA MODELING: .................................................................................................... 39 3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................... 41 4 MARKET DYNAMICS .............................................................................. 43 4.1 DRIVERS ............................................................................................................................... 44 4.1.1 INCREASING INCIDENCES/PREVALENCE OF MIGRAINE .......................................................... 44 4.1.2 RISING APPROVAL FOR THERAPEUTIC MIGRAINE PRODUCTS .......................................... 44 4.2 RESTRAINTS .............................................................................................................. 46 4.2.1 VOLUNTARY PRODUCT RECALL BY MARKET PLAYERS ....................................................... 46 4.3 OPPORTUNITY ............................................................................................................... 47 4.3.1 ONGOING CLINICAL TRIALS ASSOCIATED WITH MIGRAINE EFFICACY AND SAFETY .................. 47 4.4 PORTER'S FIVE FORCES MODEL ............................................................................. 49 4.4.1 THREAT OF NEW ENTRANTS .......................................................................................... 49 4.4.2 BARGAINING POWER OF SUPPLIERS ..................................................................... 49 4.4.3 THREAT OF SUBSTITUTES ......................................................................................... 50 4.4.4 BARGAINING POWER OF BUYERS ................................................................................. 50 4.4.5 INTENSITY OF RIVALRY ................................................................................................ 50 4.5 IMPACT OF COVID-19 ON GLOBAL MIGRAINE MARKET ......................................... 50 5 GLOBAL MIGRAINE MARKET, BY MIGRAINE TYPE .................................... 53 5.1 OVERVIEW ........................................................................................................ 53 5.2 MIGRAINE WITH AURA ........................................................................................ 55 5.3 MIGRAINE WITHOUT AURA ........................................................................................... 55 5.4 OTHERS ................................................................................................................. 56 6 GLOBAL MIGRAINE MARKET, BY TREATMENT ............................................ 57 6.1 OVERVIEW ......................................................................................................................... 57 6.2 MEDICATION ........................................................................................................ 60 6.2.1 CGRP INHIBITORS .......................................................................................................... 61 6.2.1.1 RIMEGEPANT ........................................................................................................ 61 6.2.1.2 UBROGEPANT ................................................................................................. 62 6.2.1.3 OTHERS ....................................................................................................................... 62 6.2.2 TRIPTANS ..................................................................................................................... 63 6.2.2.1 SUMATRIPTAN SUCCINATE ........................................................................................ 63 6.2.2.2 ZOLMITRIPTAN .......................................................................................................... 64 6.2.2.3 RIZATRIPTAN ........................................................................................................ 64 6.2.2.4 OTHERS ......................................................................................................... 65 6.2.3 ERGOTS ................................................................................................................. 65 6.2.3.1 DIHYDROERGOTAMINE .................................................................................................. 66 6.2.3.2 ERGOTAMINE TARTRATE ................................................................................... 66 6.2.3.3 OTHERS .......................................................................................................... 67 6.2.4 ACETYLCHOLINE INHIBITORS/ NEUROTOXINS ............................................................... 67 6.2.5 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) ................................................... 68 6.2.6 BETA-BLOCKERS .............................................................................................................. 68 6.2.7 CALCIUM CHANNEL BLOCKERS ........................................................................................ 69 6.2.8 DITANS ...................................................................................................................... 69 6.2.9 OTHERS .................................................................................................................. 70 6.3 DEVICE-BASED THERAPIES .................................................................. 70 6.3.1 ELECTRICAL NEUROMODULATION DEVICE ............................................................ 71 6.3.2 TRANSCRANIAL MAGNETIC STIMULATION DEVICE .........................................................72 6.3.3 VAGUS NERVE STIMULATION DEVICE .................................................................72 6.3.4 OTHERS ......................................................................................................... 73 7 GLOBAL MIGRAINE MARKET, BY DISTRIBUTION CHANNEL ........................ 74 7.1 OVERVIEW ............................................................................................................................ 74 7.2 ONLINE ............................................................................................................. 75 7.3 OFFLINE ............................................................................................................................ 76 8 GLOBAL MIGRAINE MARKET, BY REGION .................................................... 77 8.1 OVERVIEW .............................................................................................................................. 77 8.2 NORTH AMERICA ....................................................................................................................... 78 8.2.1 US........................................................................................................................................ 83 8.2.2 CANADA ................................................................................................................................... 86 8.3 EUROPE ....................................................................................................................... 90 8.3.1 GERMANY ........................................................................................................................... 95 8.3.2 FRANCE .................................................................................................................................. 98 8.3.3 UK .................................................................................................................................. 101 8.3.4 ITALY ..................................................................................................................... 104 8.3.5 SPAIN ..................................................................................................................... 108 8.3.6 REST OF EUROPE .................................................................................................................. 112 8.4 ASIA-PACIFIC ...................................................................................................................... 116 8.4.1 CHINA ................................................................................................................... 122 8.4.2 INDIA ................................................................................................................................. 125 8.4.3 JAPAN ........................................................................................................................... 128 8.4.4 SOUTH KOREA ................................................................................................................. 131 8.4.5 AUSTRALIA ........................................................................................................................... 135 8.4.6 NEW ZEALAND ........................................................................................................139 8.4.7 REST OF ASIA-PACIFIC .......................................................................................................... 143 8.5 REST OF THE WORLD ............................................................................................................. 147 8.5.1 MIDDLE EAST ............................................................................................................... 152 8.5.2 LATIN AMERICA ........................................................................................................................ 155 8.5.3 AFRICA ........................................................................................................................... 158 9 COMPETITIVE LANDSCAPE ...................................................................... 163 9.1 INTRODUCTION ............................................................... 9.2 MARKET SHARE ANALYSIS, 2023 ......................................................................... 163 9.3 COMPETITOR DASHBOARD................................................................................................................164 9.4 PUBLIC PLAYERS STOCK SUMMARY ...................................................................................165 9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ..................................................... 165 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ........................................................... 166 9.6.1 PRODUCT LAUNCH ...................................................................................................... 166 9.6.2 AGREEMENT .............................................................................................................. 166 9.6.3 PRODUCT APPROVAL ........................................................................................ 167 9.6.4 COLLABORATION ................................................................................................................. 168 9.6.5 PRODUCT EXPANSION ............................................................................................................ 168 10 COMPANY PROFILES ..................................................................................... 169 10.1 AMGEN INC............................................................................................................................. 169 10.1.1 COMPANY OVERVIEW ....................................................................................................... 169 10.1.2 FINANCIAL OVERVIEW ....................................................................................................... 170 10.1.3 PRODUCTS OFFERED ........................................................................................................... 171 10.1.4 KEY DEVELOPMENTS ....................................................................................................... 171 10.1.5 SWOT ANALYSIS ................................................................................................................ 171 10.1.6 KEY STRATEGIES ................................................................................................................. 172 10.2 ELI LILLY AND COMPANY .................................................................................................. 173 10.2.1 COMPANY OVERVIEW ................................................................................................... 173 10.2.2 FINANCIAL OVERVIEW ..................................................................................................174 10.2.3 PRODUCTS OFFERED ............................................................................................................174 10.2.4 KEY DEVELOPMENTS ................................................................................................................... 175 10.2.5 SWOT ANALYSIS ................................................................................................................. 176 10.2.6 KEY STRATEGIES ............................................................................................................... 176 10.3 ABBVIE INC. ................................................................................................................................. 177 10.3.1 COMPANY OVERVIEW .......................................................................................................... 177 10.3.2 FINANCIAL OVERVIEW .............................................................................................. 178 10.3.3 PRODUCTS OFFERED ..................................................................................................178 10.3.4 KEY DEVELOPMENTS .................................................................................................179 10.3.5 KEY STRATEGIES ............................................................................................................ 179 10.4 BAUSCH HEALTH COMPANIES INC. ................................................................................ 181 10.4.1 COMPANY OVERVIEW ............................................................................................... 181 10.4.2 FINANCIAL OVERVIEW ....................................................................................................... 182 10.4.3 PRODUCTS OFFERED ..................................................................................................... 182 10.4.4 KEY DEVELOPMENTS ............................................................................................... 182 10.4.5 KEY STRATEGIES ............................................................................................183 10.5 GSK PLC ................................................................................................................................... 184 10.5.1 COMPANY OVERVIEW .............................................................................................................184 10.5.2 FINANCIAL OVERVIEW ............................................................................................. 185 10.5.3 PRODUCT OFFERED ............................................................................................. 186 10.5.4 KEY DEVELOPMENTS .................................................................................................. 186 10.5.5 SWOT ANALYSIS ......................................................................................................... 186 10.5.6 KEY STRATEGIES ............................................................................................................ 187 10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. ............................................................. 188 10.6.1 COMPANY OVERVIEW ............................................................................................. 188 10.6.2 FINANCIAL OVERVIEW ................................................................................................... 189 10.6.3 PRODUCTS OFFERED ........................................................................................................ 190 10.6.4 KEY DEVELOPMENTS ....................................................................................................... 190 10.6.5 SWOT ANALYSIS .............................................................................................................. 191 10.6.6 KEY STRATEGIES .................................................................................................... 191 10.7 PFIZER INC. ........................................................................................................................ 192 10.7.1 COMPANY OVERVIEW ....................................................................................................... 192 10.7.2 FINANCIAL OVERVIEW .......................................................................................................... 193 10.7.3 PRODUCTS OFFERED .......................................................................................................... 193 10.7.4 KEY DEVELOPMENTS ............................................................................................................... 194 10.7.5 KEY STRATEGIES ................................................................................................................. 194 10.8 THERANICA BIO-ELECTRONICS LTD....................................................................................... 195 10.8.1 COMPANY OVERVIEW .......................................................................................................... 195 10.8.2 FINANCIAL OVERVIEW ............................................................................................................... 196 10.8.3 PRODUCTS OFFERED ..................................................................................................................196 10.8.4 KEY DEVELOPMENTS ................................................................................................................ 196 10.8.5 KEY STRATEGIES ........................................................................................................................ 196 10.9 CEFALY ..................................................................................................................................................... 197 10.9.1 COMPANY OVERVIEW ................................................................................................................... 197 10.9.2 FINANCIAL OVERVIEW .................................................................................................................................... 197 10.9.3 PRODUCTS OFFERED ...................................................................................................................................... 197 10.9.4 KEY DEVELOPMENTS ...................................................................................................................................... 197 10.9.5 KEY STRATEGIES ............................................................................................................................................ 197 10.10 ASTRAZENECA................................................................................................................. 199 10.10.1 COMPANY OVERVIEW ..................................................................................................................................... 199 10.10.2 FINANCIAL OVERVIEW .................................................................................................................................... 200 10.10.3 PRODUCTS OFFERED ...................................................................................................................................... 201 10.10.4 KEY DEVELOPMENTS ...................................................................................................................................... 201 10.10.5 SWOT ANALYSIS ............................................................................................................................................ 201 10.10.6 KEY STRATEGIES ............................................................................................................................................ 202 10.11 DATA CITATIONS .......................................................................................................... 204
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 39 TABLE 2 GLOBAL MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 54 TABLE 3 GLOBAL MIGRAINE MARKET, FOR MIGRAINE WITH AURA, BY REGION, 2019–2032 (USD MILLION) 55 TABLE 4 GLOBAL MIGRAINE MARKET, FOR MIGRAINE WITHOUT AURA, BY REGION, 2019–2032 (USD MILLION) 55 TABLE 5 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 56 TABLE 6 GLOBAL MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 59 TABLE 7 GLOBAL MIGRAINE MARKET, FOR MEDICATION, BY REGION, 2019–2032 (USD MILLION) 60 TABLE 8 GLOBAL MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 60 TABLE 9 GLOBAL MIGRAINE MARKET, FOR CGRP INHIBITORS, BY REGION, 2019–2032 (USD MILLION) 61 TABLE 10 GLOBAL MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 61 TABLE 11 GLOBAL MIGRAINE MARKET, FOR RIMEGEPANT, BY REGION, 2019–2032 (USD MILLION) 61 TABLE 12 GLOBAL MIGRAINE MARKET, FOR UBROGEPANT, BY REGION, 2019–2032 (USD MILLION) 62 TABLE 13 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 62 TABLE 14 GLOBAL MIGRAINE MARKET, FOR TRIPTANS, BY REGION, 2019–2032 (USD MILLION) 63 TABLE 15 GLOBAL MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 63 TABLE 16 GLOBAL MIGRAINE MARKET, FOR SUMATRIPTAN SUCCINATE, BY REGION, 2019–2032 (USD MILLION) 63 TABLE 17 GLOBAL MIGRAINE MARKET, FOR ZOLMITRIPTAN, BY REGION, 2019–2032 (USD MILLION) 64 TABLE 18 GLOBAL MIGRAINE MARKET, FOR RIZATRIPTAN, BY REGION, 2019–2032 (USD MILLION) 64 TABLE 19 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 65 TABLE 20 GLOBAL MIGRAINE MARKET, FOR ERGOTS, BY REGION, 2019–2032 (USD MILLION) 65 TABLE 21 GLOBAL MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 65 TABLE 22 GLOBAL MIGRAINE MARKET, FOR DIHYDROERGOTAMINE, BY REGION, 2019–2032 (USD MILLION) 66 TABLE 23 GLOBAL MIGRAINE MARKET, FOR ERGOTAMINE TARTRATE, BY REGION, 2019–2032 (USD MILLION) 66 TABLE 24 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 67 TABLE 25 GLOBAL MIGRAINE MARKET, FOR ACETYLCHOLINE INHIBITORS/ NEUROTOXINS, BY REGION, 2019–2032 (USD MILLION) 67 TABLE 26 GLOBAL MIGRAINE MARKET, FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2019–2032 (USD MILLION) 68 TABLE 27 GLOBAL MIGRAINE MARKET, FOR BETA-BLOCKERS, BY REGION, 2019–2032 (USD MILLION) 68 TABLE 28 GLOBAL MIGRAINE MARKET, FOR CALCIUM CHANNEL BLOCKERS, BY REGION, 2019–2032 (USD MILLION) 69 TABLE 29 GLOBAL MIGRAINE MARKET, FOR DITANS, BY REGION, 2019–2032 (USD MILLION) 69 TABLE 30 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 70 TABLE 31 GLOBAL MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY REGION, 2019–2032 (USD MILLION) 70 TABLE 32 GLOBAL MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 71 TABLE 33 GLOBAL MIGRAINE MARKET, FOR ELECTRICAL NEUROMODULATION DEVICE, BY REGION, 2019–2032 (USD MILLION) 71 TABLE 34 GLOBAL MIGRAINE MARKET, FOR TRANSCRANIAL MAGNETIC STIMULATION DEVICE, BY REGION, 2019–2032 (USD MILLION) 72 TABLE 35 GLOBAL MIGRAINE MARKET, FOR VAGUS NERVE STIMULATION DEVICE, BY REGION, 2019–2032 (USD MILLION) 72 TABLE 36 GLOBAL MIGRAINE MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 73 TABLE 37 GLOBAL MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 75 TABLE 38 GLOBAL MIGRAINE MARKET, FOR ONLINE, BY REGION, 2019–2032 (USD MILLION) 75 TABLE 39 GLOBAL MIGRAINE MARKET, FOR OFFLINE, BY REGION, 2019–2032 (USD MILLION) 76 TABLE 40 GLOBAL MIGRAINE MARKET, BY REGION, 2019–2032 (USD MILLION) 77 TABLE 41 NORTH AMERICA: MIGRAINE MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 80 TABLE 42 NORTH AMERICA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 80 TABLE 43 NORTH AMERICA: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 81 TABLE 44 NORTH AMERICA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 81 TABLE 45 NORTH AMERICA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 82 TABLE 46 NORTH AMERICA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 82 TABLE 47 NORTH AMERICA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 82 TABLE 48 NORTH AMERICA: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019–2032 (USD MILLION) 83 TABLE 49 NORTH AMERICA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 83 TABLE 50 US: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 83 TABLE 51 US: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 84 TABLE 52 US: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 84 TABLE 53 US: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 85 TABLE 54 US: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 85 TABLE 55 US: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 85 TABLE 56 US: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019–2032 (USD MILLION) 86 TABLE 57 US: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 86 TABLE 58 CANADA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 86 TABLE 59 CANADA: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 87 TABLE 60 CANADA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 87 TABLE 61 CANADA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 88 TABLE 62 CANADA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 88 TABLE 63 CANADA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 88 TABLE 64 CANADA: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019–2032 (USD MILLION) 89 TABLE 65 CANADA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 89 TABLE 66 EUROPE: MIGRAINE MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 91 TABLE 67 EUROPE: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 92 TABLE 68 EUROPE: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 92 TABLE 69 EUROPE: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 93 TABLE 70 EUROPE: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 93 TABLE 71 EUROPE: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 94 TABLE 72 EUROPE: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 94 TABLE 73 EUROPE: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019–2032 (USD MILLION) 94 TABLE 74 EUROPE: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 95 TABLE 75 GERMANY: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 95 TABLE 76 GERMANY: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 95 TABLE 77 GERMANY: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 96 TABLE 78 GERMANY: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 96 TABLE 79 GERMANY: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 97 TABLE 80 GERMANY: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 97 TABLE 81 GERMANY: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019–2032 (USD MILLION) 97 TABLE 82 GERMANY: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 98 TABLE 83 FRANCE: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 98 TABLE 84 FRANCE: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 98 TABLE 85 FRANCE: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 99 TABLE 86 FRANCE: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 99 TABLE 87 FRANCE: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 100 TABLE 88 FRANCE: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 100 TABLE 89 FRANCE: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019–2032 (USD MILLION) 100 TABLE 90 FRANCE: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 101 TABLE 91 UK: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 101 TABLE 92 UK: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 101 TABLE 93 UK: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 102 TABLE 94 UK: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 102 TABLE 95 UK: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 103 TABLE 96 UK: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 103 TABLE 97 UK: MIGRAINE MARKET, FOR DEVICE BASED THERAPY, BY TYPE, 2019–2032 (USD MILLION) 103 TABLE 98 UK: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 104 TABLE 99 ITALY: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 104 TABLE 100 ITALY: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 104 TABLE 101 ITALY: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 105 TABLE 102 ITALY: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 105 TABLE 103 ITALY: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 106 TABLE 104 ITALY: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 106 TABLE 105 ITALY: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 107 TABLE 106 ITALY: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 107 TABLE 107 SPAIN: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 108 TABLE 108 SPAIN: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 108 TABLE 109 SPAIN: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 109 TABLE 110 SPAIN: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 109 TABLE 111 SPAIN: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 110 TABLE 112 SPAIN: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 110 TABLE 113 SPAIN: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 111 TABLE 114 SPAIN: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 111 TABLE 115 REST OF EUROPE: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 112 TABLE 116 REST OF EUROPE: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 112 TABLE 117 REST OF EUROPE: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 113 TABLE 118 REST OF EUROPE: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 113 TABLE 119 REST OF EUROPE: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 114 TABLE 120 REST OF EUROPE: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 114 TABLE 121 REST OF EUROPE: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 115 TABLE 122 REST OF EUROPE: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 115 TABLE 123 ASIA-PACIFIC: MIGRAINE MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 117 TABLE 124 ASIA-PACIFIC: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 118 TABLE 125 ASIA-PACIFIC: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 118 TABLE 126 ASIA-PACIFIC: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 119 TABLE 127 ASIA-PACIFIC: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 119 TABLE 128 ASIA-PACIFIC: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 120 TABLE 129 ASIA-PACIFIC: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 120 TABLE 130 ASIA-PACIFIC: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 121 TABLE 131 ASIA-PACIFIC: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 121 TABLE 132 CHINA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 122 TABLE 133 CHINA: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 122 TABLE 134 CHINA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 122 TABLE 135 CHINA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 123 TABLE 136 CHINA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 123 TABLE 137 CHINA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 124 TABLE 138 CHINA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 124 TABLE 139 CHINA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 124 TABLE 140 INDIA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 125 TABLE 141 INDIA: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 125 TABLE 142 INDIA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 126 TABLE 143 INDIA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 126 TABLE 144 INDIA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 127 TABLE 145 INDIA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 127 TABLE 146 INDIA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 128 TABLE 147 INDIA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 128 TABLE 148 JAPAN: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 128 TABLE 149 JAPAN: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 129 TABLE 150 JAPAN: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 129 TABLE 151 JAPAN: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 130 TABLE 152 JAPAN: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 130 TABLE 153 JAPAN: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 130 TABLE 154 JAPAN: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 131 TABLE 155 JAPAN: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 131 TABLE 156 SOUTH KOREA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 131 TABLE 157 SOUTH KOREA: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 132 TABLE 158 SOUTH KOREA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 132 TABLE 159 SOUTH KOREA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 133 TABLE 160 SOUTH KOREA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 133 TABLE 161 SOUTH KOREA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 133 TABLE 162 SOUTH KOREA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 134 TABLE 163 SOUTH KOREA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 134 TABLE 164 AUSTRALIA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 135 TABLE 165 AUSTRALIA: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 135 TABLE 166 AUSTRALIA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 136 TABLE 167 AUSTRALIA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 136 TABLE 168 AUSTRALIA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 137 TABLE 169 AUSTRALIA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 137 TABLE 170 AUSTRALIA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 138 TABLE 171 AUSTRALIA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 138 TABLE 172 NEW ZEALAND: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 139 TABLE 173 NEW ZEALAND: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 139 TABLE 174 NEW ZEALAND: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 140 TABLE 175 NEW ZEALAND: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 140 TABLE 176 NEW ZEALAND: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 141 TABLE 177 NEW ZEALAND: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 141 TABLE 178 NEW ZEALAND: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 142 TABLE 179 NEW ZEALAND: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 142 TABLE 180 REST OF ASIA-PACIFIC: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 143 TABLE 181 REST OF ASIA-PACIFIC: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 143 TABLE 182 REST OF ASIA-PACIFIC: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 144 TABLE 183 REST OF ASIA-PACIFIC: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE, 2019–2032 (USD MILLION) 144 TABLE 184 REST OF ASIA-PACIFIC: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE, 2019–2032 (USD MILLION) 145 TABLE 185 REST OF ASIA-PACIFIC: MIGRAINE MARKET, FOR ERGOTS, BY TYPE, 2019–2032 (USD MILLION) 145 TABLE 186 REST OF ASIA-PACIFIC: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 146 TABLE 187 REST OF ASIA-PACIFIC: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 146 TABLE 188 REST OF THE WORLD MIGRAINE MARKET, BY REGION, 2019–2032 (USD MILLION) 148 TABLE 189 REST OF THE WORLD: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 149 TABLE 190 REST OF THE WORLD: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 149 TABLE 191 REST OF THE WORLD: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 150 TABLE 192 REST OF THE WORLD: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE 2019–2032 (USD MILLION) 150 TABLE 193 REST OF THE WORLD: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE 2019–2032 (USD MILLION) 151 TABLE 194 REST OF THE WORLD: MIGRAINE MARKET, FOR ERGOTS, BY TYPE 2019–2032 (USD MILLION) 151 TABLE 195 REST OF THE WORLD: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE 2019–2032 (USD MILLION) 151 TABLE 196 REST OF THE WORLD: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 152 TABLE 197 MIDDLE EAST: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 152 TABLE 198 MIDDLE EAST: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 152 TABLE 199 MIDDLE EAST: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 153 TABLE 200 MIDDLE EAST: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE 2019–2032 (USD MILLION) 153 TABLE 201 MIDDLE EAST: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE 2019–2032 (USD MILLION) 154 TABLE 202 MIDDLE EAST: MIGRAINE MARKET, FOR ERGOTS, BY TYPE 2019–2032 (USD MILLION) 154 TABLE 203 MIDDLE EAST: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE 2019–2032 (USD MILLION) 154 TABLE 204 MIDDLE EAST: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 155 TABLE 205 LATIN AMERICA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 155 TABLE 206 LATIN AMERICA: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 155 TABLE 207 LATIN AMERICA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 156 TABLE 208 LATIN AMERICA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE 2019–2032 (USD MILLION) 156 TABLE 209 LATIN AMERICA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE 2019–2032 (USD MILLION) 157 TABLE 210 LATIN AMERICA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE 2019–2032 (USD MILLION) 157 TABLE 211 LATIN AMERICA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE 2019–2032 (USD MILLION) 157 TABLE 212 LATIN AMERICA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 158 TABLE 213 AFRICA: MIGRAINE MARKET, BY MIGRAINE TYPE, 2019–2032 (USD MILLION) 158 TABLE 214 AFRICA: MIGRAINE MARKET, BY TREATMENT, 2019–2032 (USD MILLION) 158 TABLE 215 AFRICA: MIGRAINE MARKET, FOR MEDICATION, BY TYPE, 2019–2032 (USD MILLION) 159 TABLE 216 AFRICA: MIGRAINE MARKET, FOR CGRP INHIBITORS, BY TYPE 2019–2032 (USD MILLION) 159 TABLE 217 AFRICA: MIGRAINE MARKET, FOR TRIPTANS, BY TYPE 2019–2032 (USD MILLION) 160 TABLE 218 AFRICA: MIGRAINE MARKET, FOR ERGOTS, BY TYPE 2019–2032 (USD MILLION) 160 TABLE 219 AFRICA: MIGRAINE MARKET, FOR DEVICE-BASED THERAPIES, BY TYPE 2019–2032 (USD MILLION) 160 TABLE 220 AFRICA: MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 161 TABLE 221 PRODUCT LAUNCH 166 TABLE 222 AGREEMENT 166 TABLE 223 PRODUCT APPROVAL 167 TABLE 224 COLLABORATION 168 TABLE 225 PRODUCT EXPANSION 168 TABLE 226 AMGEN INC.: PRODUCTS OFFERED 171 TABLE 227 AMGEN INC.: KEY DEVELOPMENTS 171 TABLE 228 ELI LILLY AND COMPANY: PRODUCTS OFFERED 174 TABLE 229 ELI LILLY AND COMPANY: KEY DEVELOPMENTS 175 TABLE 230 ABBVIE INC.: PRODUCTS OFFERED 178 TABLE 231 ABBVIE INC.: KEY DEVELOPMENTS 179 TABLE 232 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED 182 TABLE 233 GSK PLC: PRODUCTS OFFERED 186 TABLE 234 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 190 TABLE 235 SYSMEX CORPORATION: KEY DEVELOPMENTS 190 TABLE 236 PFIZER INC: PRODUCT OFFERED 193 TABLE 237 PFIZER INC: KEY DEVELOPMENTS 194 TABLE 238 THERANICA BIO-ELECTRONICS LTD: PRODUCT OFFERED 196 TABLE 239 THERANICA BIO-ELECTRONICS LTD: KEY DEVELOPMENTS 196 TABLE 240 3M: PRODUCT OFFERED 197 TABLE 241 ASTRAZENECA: PRODUCT OFFERED 201 LIST OF FIGURES FIGURE 1 GLOBAL MIGRAINE MARKET: STRUCTURE 24 FIGURE 2 GLOBAL MIGRAINE MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 43 FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 45 FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032) 47 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL MIGRAINE MARKET 49 FIGURE 6 GLOBAL MIGRAINE MARKET MIGRAINE TYPE SEGMENT, 2023 & 2032 (USD MILLION) 53 FIGURE 7 GLOBAL MIGRAINE MARKET, BY MIGRAINE TYPE, 2023 & 2032 (USD MILLION) 54 FIGURE 8 GLOBAL MIGRAINE MARKET SHARE (%), BY MIGRAINE TYPE, 2023 54 FIGURE 9 GLOBAL MIGRAINE MARKET, TREATMENT SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 58 FIGURE 10 GLOBAL MIGRAINE MARKET, BY TREATMENT, 2023 & 2032 (USD MILLION) 59 FIGURE 11 GLOBAL MIGRAINE MARKET SHARE (%), BY TREATMENT, 2023 59 FIGURE 12 GLOBAL MIGRAINE MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION) 74 FIGURE 13 GLOBAL MIGRAINE MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD MILLION) 74 FIGURE 14 GLOBAL MIGRAINE MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023 75 FIGURE 15 GLOBAL MIGRAINE MARKET, BY REGION, 2023 & 2032 (USD MILLION) 77 FIGURE 16 GLOBAL MIGRAINE MARKET SHARE (%), BY REGION, 2023 78 FIGURE 17 NORTH AMERICA MARKET ANALYSIS: MIGRAINE MARKET, 2019-2032 (USD MILLION) 79 FIGURE 18 NORTH AMERICA: MIGRAINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 79 FIGURE 19 NORTH AMERICA: MIGRAINE MARKET SHARE (%), BY COUNTRY, 2023 80 FIGURE 20 EUROPE MARKET ANALYSIS: MIGRAINE MARKET, 2019-2032 (USD MILLION) 90 FIGURE 21 EUROPE: MIGRAINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 91 FIGURE 22 EUROPE: MIGRAINE MARKET SHARE (%), BY COUNTRY, 2023 92 FIGURE 23 ASIA-PACIFIC MARKET ANALYSIS: MIGRAINE MARKET, 2019-2032 116 FIGURE 24 ASIA-PACIFIC: MIGRAINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 117 FIGURE 25 ASIA-PACIFIC: MIGRAINE MARKET SHARE (%), BY COUNTRY, 2023 118 FIGURE 26 REST OF THE WORLD MARKET ANALYSIS: MIGRAINE MARKET, 2019-2032 (USD MILLION) 147 FIGURE 27 REST OF THE WORLD: MIGRAINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 148 FIGURE 28 REST OF THE WORLD: MIGRAINE MARKET SHARE, BY COUNTRY, 2023 (%) 149 FIGURE 29 GLOBAL MIGRAINE MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 163 FIGURE 30 COMPETITOR DASHBOARD: GLOBAL MIGRAINE MARKET 164 FIGURE 31 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 170 FIGURE 32 AMGEN INC.: SWOT ANALYSIS 171 FIGURE 33 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 174 FIGURE 34 ELI LILLY AND COMPANY: SWOT ANALYSIS 176 FIGURE 35 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT 178 FIGURE 36 BAUSCH HEALTH COMPANIES INC.: FINANCIAL OVERVIEW SNAPSHOT 182 FIGURE 37 GSK PLC: FINANCIAL OVERVIEW SNAPSHOT 185 FIGURE 38 GSK PLC: SWOT ANALYSIS 186 FIGURE 39 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT 189 FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS 191 FIGURE 41 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT 193 FIGURE 42 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 200 FIGURE 43 ASTRAZENECA: SWOT ANALYSIS 201

提及公司

Sanofi SAAbbott LaboratoriesTeva Pharmaceutical Industries LimitedAllergan PlcPfizer IncAstraZenecaJohnson & JohnsonEndo International PlcGlaxoSmithKline PlcImpax Laboratories.and others

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們